Targeting IL-22 and IL-22R protects against experimental osteoarthritis.

Yi, Changhua; Yi, Yongxiang; Wei, Jie; Jin, Qingwen; Li, Junwei; Sacitharan, Pradeep Kumar

Yi, Changhua; Yi, Yongxiang; Wei, Jie; Jin, Qingwen; Li, Junwei; Sacitharan, Pradeep Kumar.

Afiliação

Yi C; Department of Infectious Diseases, The Second Hospital of Nanjing, The Affiliated Hospital of Nanjing University of Chinese Medicine, #1 Zhongfu Road, Nanjing, Jiangsu Province, China.
Yi Y; College of Medical Laboratory, Shaoyang University, ShaoYang, 422000, Hunan Province, China.
Wei J; Department of General Surgery, The Second Hospital of Nanjing, The Affiliated Hospital of Nanjing University of Chinese Medicine, #1 Zhongfu Road, Nanjing, Jiangsu Province, China.
Jin Q; Department of Infectious Diseases, The Second Hospital of Nanjing, The Affiliated Hospital of Nanjing University of Chinese Medicine, #1 Zhongfu Road, Nanjing, Jiangsu Province, China.
Li J; College of Medical Laboratory, Shaoyang University, ShaoYang, 422000, Hunan Province, China.
Sacitharan PK; Department of Neurology, The Sir Run Run Hospital, Nanjing Medical University, #109 Longmian Avenue, Jiangning District, Nanjing, Jiangsu Province, China.

Cell Mol Immunol ; 18(5): 1329-1331, 2021 05.

Article em En | MEDLINE | ID: mdl-32636527

Assuntos

Interleucinas/metabolismo; Osteoartrite/metabolismo; Receptores de Interleucina/metabolismo; Animais; Anticorpos Neutralizantes/farmacologia; Condrócitos/efeitos dos fármacos; Condrócitos/metabolismo; Condrócitos/patologia; Humanos; Camundongos; Osteoartrite/patologia; Transdução de Sinais/efeitos dos fármacos; Interleucina 22

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoartrite / Interleucinas / Receptores de Interleucina Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google